Curative Biotechnology, Inc. (CUBT)
USD 0.01
(5.93%)
USD 0.01
(5.93%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -5.81 Million USD | -3.79% |
| 2022 | -5.6 Million USD | -4.95% |
| 2021 | -5.34 Million USD | -14.35% |
| 2020 | -4.67 Million USD | -1506.9% |
| 2019 | 331.95 Thousand USD | 1209.69% |
| 2018 | -29.91 Thousand USD | -30.16% |
| 2017 | -22.98 Thousand USD | -32.09% |
| 2016 | -17.4 Thousand USD | -109.12% |
| 2015 | 190.83 Thousand USD | 344.92% |
| 2014 | -77.91 Thousand USD | -23.41% |
| 2013 | -63.13 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -899.34 Thousand USD | 55.89% |
| 2024 Q2 | -697.74 Thousand USD | 22.42% |
| 2023 Q1 | -965.83 Thousand USD | 35.73% |
| 2023 FY | -3.95 Million USD | 29.4% |
| 2023 Q4 | -2.03 Million USD | -148.6% |
| 2023 Q3 | -820.12 Thousand USD | -521.44% |
| 2023 Q2 | -131.97 Thousand USD | 86.34% |
| 2022 FY | -5.6 Million USD | -4.95% |
| 2022 Q4 | -1.5 Million USD | -5.95% |
| 2022 Q3 | -1.41 Million USD | -10.17% |
| 2022 Q2 | -1.28 Million USD | 7.79% |
| 2022 Q1 | -1.39 Million USD | -49.18% |
| 2021 FY | -5.34 Million USD | -14.35% |
| 2021 Q4 | -935.93 Thousand USD | 7.85% |
| 2021 Q2 | -2.59 Million USD | -227.33% |
| 2021 Q1 | -793 Thousand USD | 84.22% |
| 2021 Q3 | -1.01 Million USD | 60.87% |
| 2020 Q2 | -1375.00 USD | -100.38% |
| 2020 Q1 | 363.64 Thousand USD | 2.03% |
| 2020 FY | -4.67 Million USD | -1506.9% |
| 2020 Q4 | -5.02 Million USD | -66784.21% |
| 2020 Q3 | -7513.00 USD | -446.4% |
| 2019 Q4 | 356.42 Thousand USD | 6830.0% |
| 2019 FY | 331.95 Thousand USD | 1209.69% |
| 2019 Q3 | -5296.00 USD | 0.0% |
| 2019 Q2 | -5296.00 USD | 61.84% |
| 2019 Q1 | -13.87 Thousand USD | 0.0% |
| 2018 FY | -29.91 Thousand USD | -30.16% |
| 2017 FY | -22.98 Thousand USD | -32.09% |
| 2016 FY | -17.4 Thousand USD | -109.12% |
| 2015 FY | 190.83 Thousand USD | 344.92% |
| 2014 FY | -77.91 Thousand USD | -23.41% |
| 2014 Q1 | -49.12 Thousand USD | -203.8% |
| 2013 Q1 | -23.03 Thousand USD | 0.0% |
| 2013 Q4 | -16.17 Thousand USD | 0.0% |
| 2013 FY | -63.13 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -335.609% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 16.692% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 110.98% |
| Nascent Biotech, Inc. | -2.08 Million USD | -178.647% |
| Rebus Holdings, Inc. | -1.02 Million USD | -470.319% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 108.931% |
| Qrons Inc. | -789.34 Thousand USD | -636.97% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -819.859% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 90.707% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -1300.132% |
| Skye Bioscience, Inc. | -37.64 Million USD | 84.547% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 92.24% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 11.54% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -2027.729% |
| SQZ Biotechnologies Company | -79.46 Million USD | 92.679% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -101.122% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -219.537% |
| Mesoblast Limited | -87.95 Million USD | 93.386% |
| Marizyme, Inc. | -65.34 Million USD | 91.098% |
| Genus plc | 7.9 Million USD | 173.636% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 46.59% |
| Pharming Group N.V. | -10.54 Million USD | 44.85% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -168.099% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -56.789% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 34.224% |
| ContraFect Corporation | -65.15 Million USD | 91.071% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -19.058% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -236.753% |
| IMV Inc. | -36.48 Million USD | 84.056% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 27.823% |
| MultiCell Technologies, Inc. | -380.07 USD | -1530474.105% |
| ONE Bio Corp. | 8.67 Million USD | 167.045% |
| Accustem Sciences Inc. | -3.74 Million USD | -55.275% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 88.746% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -359.087% |
| Q BioMed Inc. | -2.05 Million USD | -183.479% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -55.833% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -144.333% |
| Biomind Labs Inc. | -1.21 Million USD | -379.055% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 90.26% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -87.546% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 26.393% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -198.436% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -38743.837% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 63.348% |
| GB Sciences, Inc. | -1.36 Million USD | -327.212% |
| Alpha Cognition Inc. | -13.77 Million USD | 57.762% |
| HST Global, Inc. | -146.21 Thousand USD | -3878.697% |
| CSL Limited | 2.64 Billion USD | 100.22% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -231.511% |
| Halberd Corporation | -79.67 Thousand USD | -7201.136% |
| Enzolytics Inc. | -2.17 Million USD | -167.235% |
| Agentix Corp. | -1.37 Million USD | -323.316% |
| Resverlogix Corp. | -3.61 Million USD | -61.143% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -83.426% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 98.028% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 6035.972% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 184.009% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -46.42% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -92.234% |
| AVAX Technologies, Inc. | -6.41 Million USD | 9.299% |
| Zenith Capital Corp. | -10.59 Million USD | 45.1% |
| Genscript Biotech Corporation | -95.47 Million USD | 93.907% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -24929.055% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -40.312% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -9524.742% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -190.121% |
| Kadimastem Ltd | -3.3 Million USD | -75.886% |
| Helix BioMedix, Inc. | -1.05 Million USD | -450.846% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -52.324% |
| BioStem Technologies, Inc. | -8.48 Million USD | 31.424% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -1218.002% |
| LadRx Corporation | 400.44 Thousand USD | 1552.704% |
| Cell Source, Inc. | -5.32 Million USD | -9.322% |
| Regen BioPharma, Inc. | 1.02 Million USD | 668.364% |
| Regen BioPharma, Inc. | 1.02 Million USD | 668.364% |
| NovAccess Global Inc. | -4.76 Million USD | -21.976% |
| Affymax, Inc. | -14.42 Million USD | 59.67% |
| Itoco Inc. | -1.86 Million USD | -211.25% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -30.944% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -248.547% |
| Mobile Lads Corp. | -2.26 Million USD | -157.026% |
| CytoDyn Inc. | -49.84 Million USD | 88.328% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -7260.537% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -2450.006% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -517.852% |
| SYBLEU INC | -180.3 Thousand USD | -3126.358% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -260.707% |
| International Stem Cell Corporation | -131 Thousand USD | -4340.651% |
| Bioxytran, Inc. | -4.28 Million USD | -35.917% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -10618.7% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -129.909% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 87.899% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -175.178% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -644.955% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -83.625% |
| Neutra Corp. | -233.46 Thousand USD | -2391.702% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 71.331% |
| PureTech Health plc | -65.69 Million USD | 91.145% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 72.646% |
| IXICO plc | -1.17 Million USD | -393.825% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 41.4% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 89.817% |
| CSL Limited | 2.64 Billion USD | 100.22% |
| Cellectis S.A. | -103.17 Million USD | 94.362% |